1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Vijaya Diagnostic Centre Limited

Vijaya Diagnostic Centre Limited

VIJAYA.NS
Vijaya Diagnostic Centre LimitedIN flagNational Stock Exchange of India
1,283.90
INR
+4.50
- -
131.89BMarket Cap
Vijaya Diagnostic Centre Limited
VIJAYA.NS
(National Stock Exchange of India)

Recent

price

1,283.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
28.7
33.21
36.92
45.32
44.98
53.57
66.29
79.12
69.46
Revenue per Share
4.5
6.13
8.28
10.76
8.29
11.62
13.99
16.81
14.67
Basic EPS, GAAP
2.89
5.74
9.56
3.5
3.9
9.33
12.54
8.54
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
1
1
1
2
- -
Dividend per Share
14.79
21.32
29.59
40.74
48.03
58.56
71.16
1
- -
Book Value per Share
19.33
26.22
34.53
45.39
52.77
50.82
64.02
79.37
- -
Tangible Book Value per Share
102
102
102
102
102
102
103
103
103
Basic Weighted Avg Shares
2,925
3,387
3,765
4,621
4,590
5,476
6,814
8,142
7,132
Sales/Revenue/Turnover
23.43
24.68
30.84
32.68
26.24
29.93
29.74
30.1
29.54
Operating Margin (%)
396
492
505
527
617
570
706
918
749
Depreciation Expense
459
625
845
1,097
846
1,188
1,438
1,730
1,506
Net Income, GAAP
29.16
25.08
24.08
24.91
24.93
24.61
25.56
25.66
25.85
Effective Tax Rate (%)
15.69
18.47
22.44
23.73
18.44
21.7
21.1
21.24
21.12
Profit Margin (%)
803
1,277
1,948
2,038
2,095
1,385
1,446
1,980
- -
Working Capital
1,350
1,417
1,297
1,703
2,330
2,391
2,964
4,000
- -
LT Debt
2,070
2,741
3,592
4,695
5,466
6,599
7,991
9,572
- -
Total Equity
- -
15.76
18.83
19.65
12.48
14.41
14.78
14.57
- -
Return on Invested Capital (%)
- -
21.34
22.91
23.03
14.73
16.82
17.02
26.58
64.94
Return on Capital (%)
- -
33.98
32.55
30.59
18.69
21.83
21.62
46.64
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
232
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
2,964
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
103
- -
Market Capitalization
108,624
103,537
101,165

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
3,072
- -
Cash, Cash Equivalents & STI
- -
2,813
- -
Accounts Receivable, Net
- -
148
- -
Inventories
- -
49
- -
Total Current Liabilities
- -
1,626
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
232
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
21.74%
19.77%
Free Cash Flow
- -
18.25%
-31.84%
Net Income, GAAP
- -
17.74%
20.3%
Sales/Revenue/Turnover
- -
17.06%
19.49%
Total Cash Common Dividend
- -
- -
100.18%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,210
1,389
1,327
1,550
5,476
2025
1,562
1,829
1,690
1,732
6,814
2026
1,881
2,052
2,194
- -
8,142

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.57
3.26
2.53
- -
11.62
2025
3.06
4.09
3.43
3.39
13.99
2026
3.76
4.2
4.66
- -
16.81

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
2
Similar Companies
SeqLL Inc. (SQL)
Joinn Laboratories(China)Co.,Ltd. (6127.HK)
LumiraDx Limited (LMDXW)
Danaher Corporation (DHR-PA)
Myriad Genetics, Inc. (MYGN)
NeoGenomics, Inc. (NEO)
Business
Vijaya Diagnostic Centre Limited, headquartered in Hyderabad, India, and founded in 1981, operates as one of India's leading diagnostic chains, providing comprehensive pathology and radiology services across a network of over 160 centres in 25 cities spanning six states including Telangana, Andhra Pradesh, Karnataka, Maharashtra, West Bengal, and the National Capital Region; core offerings encompass clinical pathology, microbiology, haematology, serology, biochemistry, molecular diagnostics, and specialized radiology modalities such as CT scans, MRI-3T, ultrasound, X-ray, PET-CT, and diagnostic cardiology, alongside over 220 basic tests, 740 routine tests, 870 specialized tests, 320 advanced radiology tests, customized health and wellness packages for diverse age groups and lifestyles, home sample collection, and corporate wellness programs. The company maintains NABL-accredited laboratories, ISO 9001:2015 certification for its flagship centre, and NABH-aligned operations, supported by more than 3,000 professionals including 300+ specialized radiologists and pathologists serving over 100 million customers. Recent developments include NCLT approval for the merger with subsidiary Medinova Diagnostic Services Limited effective April 1, 2024, alongside the completion of acquiring the remaining 37.86% stake in Medinova; expansion through commissioning nine hubs in 9MFY25 with plans for nine more hubs and six spokes, including new facilities in Bengaluru with PET-CT and 3T MRI/CT, a hub in Kasba, Kolkata, and upcoming hubs in West Bengal's Krishna Nagar and Barasat; and strong Q2 FY26 financial performance with 10.4% revenue growth to Rs 2.02 billion driven by volume increases in radiology and pathology.